LACTOLOGY FOUNDATION

Bevonium (ATC A03AB13) is a synthetic antimuscarinic (anticholinergic) agent used as an antispasmodic in functional gastrointestinal disorders, with a toxicity profile typical for quaternary ammonium anticholinergics and with no robust, breastfeeding‑specific data; in lactation it should be approached with caution and, where possible, replaced by better characterized alternatives.medpedia.framar+5

Pharmacological class and mechanism

Bevonium belongs to ATC group A03AB, “synthetic anticholinergics, quaternary ammonium compounds,” and specifically to A03AB13.atcddd.fhi+1
It is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors in the gastrointestinal tract, leading to reduced motility and spasmolysis.wikipedia+1

As a quaternary ammonium compound, bevonium is highly ionized at physiological pH and has poor penetration through the blood–brain barrier, which limits central nervous system effects compared with tertiary anticholinergics.wikipedia+1
Clinically it has been described as having both antispasmodic and bronchodilating properties, though in the A03AB13 context its use is mainly for functional bowel disorders.atcddd.fhi+1

Indications, dosing and contraindications

In the Bulgarian Framar monograph, bevonium is presented as an antimuscarinic indicated in the broader class of antimuscarinic agents used as antiparkinsonian drugs, though its ATC position is under gastrointestinal antispasmodics.medpedia.framar+1
Internationally, A03AB13 is assigned to bevonium for the treatment of functional gastrointestinal symptoms such as colicky pain, spasm, and irritable‑bowel‑type complaints.gelbe-liste+1

The official ATC/DDD documentation lists bevonium with a defined daily dose (DDD) of 0.2 (unit depending on national product form), but product‑specific dosing must follow the individual summary of product characteristics.bfarm+1
The Framar entry emphasizes that the dose should be individualized by a physician, with use only on prescription.medpedia.framar

Contraindications include hypersensitivity to bevonium or any excipient, as explicitly noted in the Bulgarian information, and the usual anticholinergic contraindications such as narrow‑angle glaucoma, urinary retention, severe prostatic hypertrophy, and certain obstructive gastrointestinal conditions, extrapolated from anticholinergic class data.rch+2

Toxicity profile and adverse effects

The toxicology of bevonium is characterized by the typical anticholinergic spectrum related to peripheral muscarinic blockade.goodrx+2
Common dose‑related adverse effects include dry mouth, decreased salivary and bronchial secretions, constipation, tachycardia, blurred vision, mydriasis, and urinary retention.wikipedia+1

At higher doses, or in overdose, anticholinergic syndrome may develop, with manifestations such as agitated delirium, restlessness, hyperthermia, flushed skin, tachycardia, and reduced bowel sounds.rch+1
Management of anticholinergic toxicity is mainly supportive (airway, breathing, circulation, cooling, benzodiazepines for agitation and seizures), with possible use of physostigmine in selected severe central toxicity cases after specialist toxicology consultation.rch

Because bevonium is a quaternary ammonium compound with limited central penetration, the risk of central anticholinergic syndrome may be lower than with tertiary agents; however, peripheral toxicity (cardiovascular, gastrointestinal, urinary) remains clinically significant, especially in the elderly and in patients with comorbidities.goodrx+2
Careful dose titration and avoidance in patients at risk of glaucoma or urinary retention are important safety measures.wikipedia+1

Use during pregnancy and lactation

Specific human data on bevonium use during breastfeeding are not available in major open sources such as LactMed or standard lactation monographs, and no detailed clinical lactation studies were found.drugbank+2
General principles for medicine use in lactation state that most drugs pass into breast milk in low amounts, and many are compatible, but compounds with strong anticholinergic activity and limited safety data warrant particular caution.medsafe+2

Quaternary ammonium anticholinergics typically have poor oral bioavailability and high polarity, which may reduce systemic exposure in the breastfed infant; however, in the absence of direct bevonium milk‑level and infant‑outcome data, it should not be considered automatically safe.kellymom+2
When symptom control requires an antispasmodic in a breastfeeding woman, it is prudent to prefer agents with established lactation safety profiles (e.g. those with pediatric formulations or documented LactMed entries), and to use the lowest effective dose for the shortest possible duration if bevonium must be used.breastfeedingnetwork+2

If bevonium is prescribed to a nursing mother, monitoring the infant for signs possibly related to anticholinergic exposure—poor feeding, constipation, unusual irritability or sedation—should be advised, and consultation of more specialized resources (InfantRisk Center, Hale’s “Medications and Mothers’ Milk,” national formulary) is recommended.medsafe+2
In mothers of preterm or medically fragile infants, or in high‑dose/long‑term bevonium therapy, temporary use of an alternative drug with better evidence or, rarely, expressing and storing milk while using a short course of medication may be discussed on a case‑by‑case basis.akronchildrens+2

Clinical and practical considerations

From a clinical standpoint, bevonium occupies a narrow and nowadays relatively uncommon niche among antispasmodic anticholinergics, with many countries favoring better studied alternatives.fass+2
For prescribers, its quaternary structure offers the theoretical advantage of reduced central effects, but does not negate peripheral risks, particularly in older patients, in those with cardiovascular disease, and in those at risk of urinary or intestinal obstruction.goodrx+2

In lactology‑oriented practice, the absence of specific lactation data means bevonium should generally be considered a second‑line option, used only when alternatives are unsuitable and after individualized risk–benefit assessment.breastfeedingnetwork+2
Clear communication with the breastfeeding mother, documentation of indications, dose, duration and infant monitoring plan are essential elements of safe use in this population.kellymom+1